Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05919680 · ClinicalTrials.gov registry record · Phase 2
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
A Phase 2 study of Intestinal Failure Associated Liver Disease, sponsored by NorthSea Therapeutics B.V..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 13
- Study locations
NCT05919680: Recruiting Phase 2 study of Intestinal Failure Associated Liver Disease, sponsored by NorthSea Therapeutics B.V..
NCT05919680 is a Phase 2 study of Intestinal Failure Associated Liver Disease that is actively recruiting participants, run by NorthSea Therapeutics B.V.. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). The trial reports 13 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05919680, a Phase 2 study of Intestinal Failure Associated Liver Disease, is actively recruiting participants, sponsored by NorthSea Therapeutics B.V..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) to receive NST-6179 (N=12/part) or matched placebo (N=6/part). Subjects in Part A will receive once daily (QD) oral administration of 800 mg (32 mL solution) NST-6179 or placebo for 4 weeks. The NST-6179 dose for Part B is planned to be 1200 mg QD for 12 weeks. Actual dose, however, will be determined during the safety review meeting.
Primary Outcome
Incidences of treatment-emergent adverse events, clinically significant chances in laboratory tests, vital signs and ECGs
Conditions Studied
Interventions
- OTHER Matched Placebo
- DRUG NST-6179 Part A
- DRUG NST-6179 Part B
Study Locations (13)
Arizona
- Mayo Clinic Scottsdale Campus - Scottsdale
California
- University of California San Francisco Medical Center - San Francisco
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Georgia
- Emory University School of Medicine - Atlanta
Illinois
- The University of Chicago Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Michigan
- Henry Ford Hospital - Detroit
Minnesota
- Mayo Clinic Rochester Campus - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
What NCT05919680 shows while recruiting
NCT05919680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Intestinal Failure Associated Liver Disease appearing as the primary indexed condition, and to 3 interventions - of which Matched Placebo is the first listed.
NCT05919680 lists 13 locations in 13 states (Arizona, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT05919680 about?
NCT05919680 is a clinical study titled "A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).". This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study ...
What is the current status of trial NCT05919680?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-01-15. Estimated completion is 2025-06-30.
What conditions does trial NCT05919680 study?
This clinical trial studies the following conditions: Intestinal Failure Associated Liver Disease.
What interventions are being tested in trial NCT05919680?
The interventions under investigation include: Matched Placebo (OTHER), NST-6179 Part A (DRUG), NST-6179 Part B (DRUG).
Who is sponsoring clinical trial NCT05919680?
This trial is sponsored by NorthSea Therapeutics B.V., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05919680 being conducted?
This trial has 13 study locations across Arizona, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05919680's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI